Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free AIDX Stock Alerts

20/20 Biolabs (AIDX) Competitors

20/20 Biolabs logo
$0.43 +0.01 (+2.74%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$0.42 -0.02 (-3.61%)
As of 09/25/2026 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AIDX vs. BMGL, MGRX, GXAI, BIAF, and IVF

Should you buy 20/20 Biolabs stock or one of its competitors? 20/20 Biolabs's main competitors and comparable companies include Basel Medical Group (BMGL), Mangoceuticals (MGRX), Gaxos.ai (GXAI), bioAffinity Technologies (BIAF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does 20/20 Biolabs compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

In the previous week, Basel Medical Group and Basel Medical Group both had 2 articles in the media. 20/20 Biolabs' average media sentiment score of 0.94 beat Basel Medical Group's score of 0.39 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company Overall Sentiment
Basel Medical Group Neutral
20/20 Biolabs Positive

Company Net Margins Return on Equity Return on Assets
Basel Medical GroupN/A N/A N/A
20/20 Biolabs N/A N/A N/A

20/20 Biolabs has lower revenue, but higher earnings than Basel Medical Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Basel Medical Group$8.90M0.66-$9.50MN/AN/A
20/20 Biolabs$2.04M2.72-$3.74M-$0.54N/A

20/20 Biolabs has a consensus price target of $5.00, suggesting a potential upside of 1,050.22%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than Basel Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

20/20 Biolabs beats Basel Medical Group on 6 of the 7 factors compared between the two stocks.

How does 20/20 Biolabs compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Mangoceuticals and Mangoceuticals both had 2 articles in the media. 20/20 Biolabs' average media sentiment score of 0.94 beat Mangoceuticals' score of 0.91 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company Overall Sentiment
Mangoceuticals Positive
20/20 Biolabs Positive

20/20 Biolabs has a net margin of 0.00% compared to Mangoceuticals' net margin of -4,794.60%. 20/20 Biolabs' return on equity of 0.00% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mangoceuticals-4,794.60% -96.39% -89.60%
20/20 Biolabs N/A N/A N/A

56.7% of Mangoceuticals shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

20/20 Biolabs has higher revenue and earnings than Mangoceuticals. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mangoceuticals$460K21.85-$20.64M-$1.01N/A
20/20 Biolabs$2.04M2.72-$3.74M-$0.54N/A

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 1,050.22%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts plainly believe 20/20 Biolabs is more favorable than Mangoceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

20/20 Biolabs beats Mangoceuticals on 11 of the 14 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

42.6% of Gaxos.ai shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, 20/20 Biolabs had 1 more articles in the media than Gaxos.ai. MarketBeat recorded 2 mentions for 20/20 Biolabs and 1 mentions for Gaxos.ai. 20/20 Biolabs' average media sentiment score of 0.94 beat Gaxos.ai's score of 0.91 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company Overall Sentiment
Gaxos.ai Positive
20/20 Biolabs Positive

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
Gaxos.ai-64.81% -38.79% -36.99%
20/20 Biolabs N/A N/A N/A

20/20 Biolabs has lower revenue, but higher earnings than Gaxos.ai. Gaxos.ai is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gaxos.ai$6.01M1.02-$3.90M-$0.50N/A
20/20 Biolabs$2.04M2.72-$3.74M-$0.54N/A

20/20 Biolabs has a consensus price target of $5.00, suggesting a potential upside of 1,050.22%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

20/20 Biolabs beats Gaxos.ai on 12 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, bioAffinity Technologies had 1 more articles in the media than 20/20 Biolabs. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 0.94 beat bioAffinity Technologies' score of 0.66 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Positive
20/20 Biolabs Positive

20/20 Biolabs has lower revenue, but higher earnings than bioAffinity Technologies. 20/20 Biolabs is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M0.77-$14.91M-$109.45N/A
20/20 Biolabs$2.04M2.72-$3.74M-$0.54N/A

20/20 Biolabs has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. 20/20 Biolabs' return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-257.30% -220.52% -136.76%
20/20 Biolabs N/A N/A N/A

20/20 Biolabs has a consensus target price of $5.00, suggesting a potential upside of 1,050.22%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

20/20 Biolabs beats bioAffinity Technologies on 11 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to INVO Fertility?

20/20 Biolabs (NASDAQ:AIDX) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 1,050.22%. INVO Fertility has a consensus price target of $20.00, suggesting a potential upside of 2,017.07%. Given INVO Fertility's stronger consensus rating and higher possible upside, analysts clearly believe INVO Fertility is more favorable than 20/20 Biolabs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, INVO Fertility had 2 more articles in the media than 20/20 Biolabs. MarketBeat recorded 4 mentions for INVO Fertility and 2 mentions for 20/20 Biolabs. INVO Fertility's average media sentiment score of 1.18 beat 20/20 Biolabs' score of 0.94 indicating that INVO Fertility is being referred to more favorably in the news media.

Company Overall Sentiment
20/20 Biolabs Positive
INVO Fertility Positive

12.0% of INVO Fertility shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 0.4% of INVO Fertility shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

20/20 Biolabs has a net margin of 0.00% compared to INVO Fertility's net margin of -116.29%. 20/20 Biolabs' return on equity of 0.00% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
INVO Fertility -116.29%-85.54%-31.05%

20/20 Biolabs has higher earnings, but lower revenue than INVO Fertility. 20/20 Biolabs is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$2.04M2.72-$3.74M-$0.54N/A
INVO Fertility$7.53M0.31-$25.13M-$33.83N/A

Summary

20/20 Biolabs and INVO Fertility tied by winning 8 of the 16 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIDX vs. The Competition

Export
Metric20/20 BiolabsHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.55M$9.82B$7.34B$13.18B
Dividend YieldN/A2.59%2.52%14.03%
P/E Ratio-0.8135.06275.8225.76
Price / Sales2.725.00627.4187.84
Price / CashN/A123.0179.5252.89
Price / BookN/A5.2410.446.30
Net Income-$3.74M$315.70M$3.51B$360.35M
7 Day Performance-6.54%0.71%-1.31%-0.23%
1 Month Performance-29.85%0.14%-4.61%-4.16%
1 Year PerformanceN/A16.65%15.01%4.58%

20/20 Biolabs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIDX
20/20 Biolabs
2.6895 of 5 stars		$0.43
+2.7%		$5.00
+1,050.2%		N/A$5.55M$2.04MN/A14
BMGL
Basel Medical Group
0.1552 of 5 stars		$7.47
+63.0%		N/A-82.5%$11.66M$8.90MN/A36
MGRX
Mangoceuticals
1.1269 of 5 stars		$0.41
+2.0%		N/A-78.4%$8.87M$460KN/A3
GXAI
Gaxos.ai
0.5667 of 5 stars		$0.67
-1.4%		N/A-66.3%$4.91M$1.93MN/A3
BIAF
bioAffinity Technologies
0.2937 of 5 stars		$7.85
-1.3%		N/A-90.0%$4.74M$6.16MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 9/27/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel